Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 260Carcinoma, Non-Small-Cell Lung 125Glioblastoma 105Breast Neoplasms 104Ovarian Neoplasms 96Carcinoma, Hepatocellular 88Brain Neoplasms 71Rectal Neoplasms 69Neoplasm Metastasis 69Lung Neoplasms 65Colonic Neoplasms 58Neoplasms 57Glioma 52Fallopian Tube Neoplasms 44Carcinoma, Renal Cell 36Gliosarcoma 31Pancreatic Neoplasms 30Melanoma 27Liver Neoplasms 26Stomach Neoplasms 21Astrocytoma 21Adenocarcinoma of Lung 21Recurrence 20Kidney Neoplasms 19Colorectal Cancer Metastatic 17Triple Negative Breast Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Sarcoma 13Prostatic Neoplasms 13

Interventions

Everolimus 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Malignancies × Bevacizumab × Clear all
NCT06717880 2025-02-12

A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Recruiting
260 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡